Web13 apr. 2024 · The big difference is that the CAR T-cell product is given on a one-time basis with dramatic benefits, while the bispecific therapy is given as ongoing treatment. The … WebRebecca Silbermann, MD, MMS, of the Knight Cancer Translational Oncology Program, Oregon Health & Science University, discusses patient-reported outcomes from the …
ASH 2024: Multiple Myeloma Highlights - The ASCO Post
Web7 mar. 2024 · With the gradual improvement of treatment regimens, the survival time of multiple myeloma (MM) patients has been significantly prolonged. Even so, MM is still a … Web9 dec. 2024 · Multiple myeloma (MM) is a clonal plasma cell neoplasm and second most common hematologic malignancy. Development of novel therapeutic agents, such as … hiit vs mict treadmill and cycle
Testicular Cancer: What Patients Need to Know - The Patient Story
Web11 apr. 2024 · Investigators observed no grade 4 or 5 AEs at the 50 mcg/kg dosing level. Investigators continued to administer MT-0169 at 5 mcg/kg to patients with relapsed multiple myeloma after filing a protocol amendment in January 2024. Web11 apr. 2024 · According to findings from a poster session presented at the 2024 Tandem Meeting, CB-011 demonstrated potent anti-tumor activity in vitro and enhanced survival in multiple myeloma xenograft models. 3 Additionally, investigators observed no adverse safety signals associated with treatment in vitro. Web13 apr. 2024 · This process takes several weeks, and to treat myeloma, what is called "bridge therapy" is used to try to sustain remission until the CAR T cells are manufactured and ready to be infused, usually after four to six weeks, whenever the product is available. In contrast, bispecific monoclonal antibodies are "off the shelf." hiit vs interval training